Aging Increases Aortic MMP-2 Activity and Angiotensin II in Nonhuman Primates
- 1 June 2003
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 41 (6), 1308-1316
- https://doi.org/10.1161/01.hyp.0000073843.56046.45
Abstract
To seek evidence that the nonhuman primate arterial wall, as it ages in the absence of atherosclerosis, exhibits alterations in pathways that are involved in the pathogenesis of experimental atherosclerosis, we assessed aortic matrix metalloproteinase-2 (MMP-2) and its regulators, ie, membrane type-1 of matrix metalloproteinase (MT1-MMP) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and the expression of angiotensin II (Ang II), angiotensin-converting enzyme (ACE), and chymase in young (6.4+/-0.7 years) and old (20.0+/-1.9 years) male monkeys. With advancing age, (1) the intimal thickness increased 3-fold and contained numerous vascular smooth muscle cells and matrix, but no inflammatory cells; (2) the intimal MMP-2 antibody-staining fraction increased by 80% (P<0.01); (3) in situ zymography showed that MMP-2 activity, mainly confined to the intima, increased 3-fold (P<0.01); (4) the MT1-MMP antibody-staining fraction increased by 150% (P<0.001), but the TIMP-2 antibody-staining fraction did not significantly change; (5) steady levels of the mRNA-staining fraction (via in situ hybridization) for MMP-2 increased 7-fold, for MT1-MMP increased 9-fold, and for TIMP-2 increased 2-fold (all P<0.001); and (6) intimal Ang II and ACE immunofluorescence were increased 5-fold and 5.6-fold, respectively, and colocalized with MMP-2. Thus, age-associated arterial remodeling and the development and progression of experimental atherosclerosis in young animals share common mechanisms, ie, MMP-2 activation and increased Ang II signaling. This might explain, in part, the dramatically exaggerated prevalence and severity of vascular diseases with aging.Keywords
This publication has 21 references indexed in Scilit:
- Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-κB by Losartan in Hypercholesterolemic RabbitsJournal of Cardiovascular Pharmacology, 2002
- Mast Cell Tissue Inhibitor of Metalloproteinase-1 Is Cleaved and Inactivated Extracellularly by α-ChymaseThe Journal of Immunology, 2001
- Involvement of Fibronectin Type II Repeats in the Efficient Inhibition of Gelatinases A and B by Long-chain Unsaturated Fatty AcidsJournal of Biological Chemistry, 2001
- Upregulation of LOX-1 Expression in Aorta of Hypercholesterolemic Rabbits: Modulation by LosartanBiochemical and Biophysical Research Communications, 2000
- Anti‐atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high‐cholesterol dietBritish Journal of Pharmacology, 1999
- Enhanced Proliferation and Migration and Altered Cytoskeletal Proteins in Early Passage Smooth Muscle Cells from Young and Old Rat Aortic ExplantsExperimental and Molecular Pathology, 1997
- Tissue Inhibitor of Metalloproteinase-2 Stimulates Fibroblast Proliferation via a cAMP-dependent MechanismJournal of Biological Chemistry, 1995
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994
- A comparison of structural features of the walls of coronary arteries from 10 different speciesPathology, 1989
- Effect of Age on Atherosclerosis Progression in Nonhuman PrimatesPublished by Springer Nature ,1987